A key challenge in preclinical studies of diabetes is the lack of translational platforms that can model the various aspects of disease progression and associated complications. In this talk, Dr. Gorski will present the development and utility of CrownBio’s unique continuum of translational platforms that model various aspects of diabetes and metabolic syndrome, and how such platforms are used to predict the efficacy and safety of anti-diabetic therapies in humans.
Specifically, she will discuss the development of the ZDSD rat model, one of the most translational rodent model of prediabetes, diabetes, and diabetic complications (such as diabetic nephropathy). She will also discuss a spontaneously dysmetabolic and diabetic non-human primate model, and how how insulin resistance and type 2 diabetes in this model bear close similarity to obesity mediated insulin resistance in humans and share case studies on the utility of this model as a platform for therapeutics that ameliorate insulin resistance.
Dr. Judith Gorski, Global Director, Scientific Engagement, Crown Bioscience Inc.
Dr. Judith Gorski is Global Director of Scientific Engagement at Crown Bioscience Inc., and is a pharmacologist with over 18 years of experience in drug discovery and development in a large pharmaceutical environment. She has extensive experience in basic research and targeted drug discovery in the disease areas of type 1 and 2 diabetes, dyslipidemia, atherosclerosis, obesity, and metabolic syndrome. Dr. Gorski has co-authored publications in Nature, Obesity, Obesity Research, Cell Metabolism, Journal of Lipid Metabolism.
Prior to joining CrownBio, Dr. Gorski’s work at Merck focused on target identification/validation and small molecule and biologics identification/optimization with the aim of recommending lead candidates for clinical development. She is an expert at establishing and validating primary, secondary and tertiary in vivo models of dyslipidemia, obesity, metabolic syndrome, and type 1 and 2 diabetes
Dr. Gorski received her Ph.D. in Neuroscience from University of Medicine and Dentistry, New Jersey.
Who Should Attend?
Scientists and decision makers in the areas of Diabetes, Obesity, Renal Disease, Cardiovascular Disease, NAFLD/NASH
Relevant Job Functions:
- Principal Scientists
- Principal Investigators
- C-level/VPs/Directors of Drug Discovery and R&D
- C-level/VPs/Directors of Preclinical Trials
- Pharmaceutical & Biotechnology companies
- Non-profit organizations
- Academia (professors, post doctoral fellows & laboratory managers)
What You Will Learn
Attendees will learn about:
- The latest rodent and non-human primate translational models to study diabetes pathology
- Modeling prediabetes, diabetes progression, and associated complications (e.g., nephropathy) in these models
- Examples of how these models are used to assess efficacy and safety of anti-diabetes therapeutics
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
CrownBio’s CVMD portfolio is a unique continuum of translational platforms that enables our clients to to model human cardiovascular and metabolic disease pathologies and use them to predict human efficacy and safety of therapeutic candidates. With unique rodent and non-human primate models and a vast set of services, we help accelerate drug development in the areas of: